People taking GLP-1 medications for type 2 diabetes (liraglutide, semaglutide, or tirzepatide) may be more likely to stop and later restart treatment than many people realize, according to research presented Sunday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Ill.
The study…
Leave a Reply